ZTS Q4 2025 Earnings
Reported Feb 12, 2026 at 7:04 AM ET · SEC Source
Q4 25 EPS
$1.48
BEAT +5.71%
Est. $1.40
Q4 25 Revenue
$2.39B
BEAT +1.09%
Est. $2.36B
vs S&P Since Q4 25
-18.7%
TRAILING MARKET
ZTS -13.0% vs S&P +5.7%
Full Year 2025 Results
FY 25 EPS
$6.41
BEAT +1.13%
Est. $6.34
FY 25 Revenue
$9.47B
BEAT +0.27%
Est. $9.44B
Market Reaction
Did ZTS Beat Earnings? Q4 2025 Results
Zoetis closed out fiscal 2025 on a firm note, posting fourth-quarter adjusted earnings of $1.48 per diluted share against a consensus estimate of $1.40, a beat of 5.71%, while revenue of $2.39 billion edged past the $2.36 billion estimate and grew 3.… Read more Zoetis closed out fiscal 2025 on a firm note, posting fourth-quarter adjusted earnings of $1.48 per diluted share against a consensus estimate of $1.40, a beat of 5.71%, while revenue of $2.39 billion edged past the $2.36 billion estimate and grew 3.0% year over year. The headline driver was a robust international segment, which expanded 8% to $1.12 billion on broad-based strength in parasiticides, diagnostics, and livestock across cattle, fish, and poultry markets, more than offsetting a 2% decline in the U.S. Segment where mAb osteoarthritis products Librela and Solensia pulled back. Full-year revenue reached $9.47 billion, with adjusted diluted EPS of $6.41 reflecting 10% organic operational growth. Analysts tracking the stock have pointed to rising pet spending and resilient livestock demand as durable tailwinds supporting the company's long-term profitability profile. Looking ahead, Zoetis guided fiscal 2026 revenue of $9.83 billion to $10.03 billion and adjusted diluted EPS of $7.00 to $7.10, underpinned by anticipated 2026 launches of its long-acting mAb pain therapies Lenivia and Portela in key international markets.
Key Takeaways
- • Growth in parasiticides portfolio including ProHeart and Simparica franchise
- • Key dermatology franchise growth (Apoquel, Cytopoint)
- • Strong international livestock growth across cattle, fish, and poultry
- • Diagnostics growth in International segment
- • Expected Fiscal Year Alignment operational changes contributed ~2.5%-3.5% to Q4 International revenue (non-recurring)
ZTS Forward Guidance & Outlook
For full year 2026, Zoetis guides revenue of $9.825 billion to $10.025 billion (3% to 5% organic operational growth), reported net income of $2.825 billion to $2.875 billion, adjusted net income of $2.975 billion to $3.025 billion (3% to 6% organic operational growth), reported diluted EPS of $6.65 to $6.75, and adjusted diluted EPS of $7.00 to $7.10. Adjusted cost of sales is expected at approximately 28.0% of revenue, adjusted SG&A expenses of $2.430 billion to $2.490 billion, adjusted R&D expenses of $715 million to $725 million, with an effective tax rate on adjusted income of approximately 20.5%. Guidance reflects foreign exchange rates as of January 20, 2026.
ZTS YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
ZTS Revenue by Segment
With YoY comparisons, source: SEC Filings
ZTS Revenue by Geography
With YoY comparisons, source: SEC Filings
“Zoetis delivered solid results in 2025, demonstrating the strength and resilience of our portfolio across species, geographies, and channels. Leadership across key brands and categories drove continued growth, even as we navigated a dynamic operating environment.”
— Kristin Peck, Q4 2025 Earnings Press Release
ZTS Earnings Trends
ZTS vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
ZTS EPS Trend
Earnings per share: estimate vs actual
ZTS Revenue Trend
Quarterly revenue: estimate vs actual
ZTS Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q4 25 BEAT FY | $1.40 | $1.48 | +5.71% | $2.39B | +1.09% |
| FY Full Year | $6.34 | $6.41 | +1.13% | $9.47B | +0.27% |
| Q3 25 BEAT | $1.62 | $1.70 | +4.83% | $2.40B | -0.23% |
| Q2 25 BEAT | $1.61 | $1.76 | +9.15% | $2.46B | +2.18% |
| Q1 25 BEAT | $1.40 | $1.48 | +5.79% | $2.22B | +1.24% |